Biotech Growth Trust plc (The) (BIOG) Ordinary 25p
- Add to watchlist
- Create an alert
- This stock can be held in a
860.00p
872.00p
1,068.00p
944.50
863.00p
852.00p
842.00p
-8.63%
16.00p (1.82%) Previous:
16.00p
39,402
n/a
GBX
Price
-
Net Asset Value (NAV)
Performance
1 week 1W | 1.92% | 1 year 1Y | 1.05% |
---|---|---|---|
1 month 1M | 3.88% | 2 years 2Y | 1.7% |
3 months 3M | 17.96% | 3 years 3Y | 25.3% |
6 months 6M | 9.01% | 5 years 5Y | 6.47% |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Trust Basics
Benchmark: | NASDAQ Biotechnology TR GBP |
---|---|
Annual management charge: | n/a |
Performance fee: | Yes |
Ongoing charge: | 1.20% |
Dividend yield: | n/a |
Dividend frequency: | None |
Total assets: | £312m |
Gross gearing: | 6% |
Market capitalisation:Market cap.: | £267m |
Shares in issue: | 30.90 million |
Legal structure | Closed Ended Investment Company |
Domicile: | United Kingdom |
ISIN | GB0000385517 |
Dividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
Objective
NET ASSET VALUE (NAV)
Estimated NAV: | 944.50p |
---|---|
Latest actual NAV: | 956.07p |
Latest actual NAV date: | 19 December 2024 |
Premium/Discount: | -8.63% |
12m average Premium/Discount: | -7.59% |
NAV frequency: | Daily |
Security | Weight |
---|---|
Amgen Inc | 9.09% |
QuantumPharm Inc | 5.69% |
Sarepta Therapeutics Inc | 5.07% |
Biogen Inc | 4.52% |
Gilead Sciences Inc | 4.46% |
Ionis Pharmaceuticals Inc | 3.81% |
Regeneron Pharmaceuticals Inc | 3.58% |
argenx SE ADR | 3.46% |
Alnylam Pharmaceuticals Inc | 3.23% |
Phathom Pharmaceuticals Inc Ordinary shares | 2.98% |
Sector | Weight |
---|---|
Healthcare | 105.17% |
Country | Weight |
---|---|
United States | 90.39% |
China | 9.36% |
Canada | 2.75% |
Germany | 1.70% |
Switzerland | 0.97% |
Key Dates
Launch date: | 23 June 1997 |
---|---|
Financial year end: | March |
Next AGM: | July 2025 |
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.